1365241-92-4

Basic information

• Product Name: N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide
• Synonyms: N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide
• CAS NO: 1365241-92-4
• Molecular Weight: 541.548
• Mol File: 1365241-92-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide(1365241-92-4)
• EPA Substance Registry System: N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide(1365241-92-4)

Safety Data

• Hazardous Substances Data: 1365241-92-4(Hazardous Substances Data)

Upstream product

• 1365243-78-2 [4-(cyclopropylcarbamoyl)-3-methylphenyl]boronic acid 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 345965-99-3 4-bromo-N-cyclopropyl-2-methylbenzamide 
• 933190-51-3 8-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 1263425-59-7 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine 
• 1206487-36-6 6,8-dibromoimidazo[1,2-b]pyridazine 
• 1365243-73-7 6,8-dibromo-3-iodoimidazo[1,2-b]pyridazine 
• 1351374-48-5 N-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1365243-96-4 6-bromo-3-iodo-N-(3,3,3-trifluoropropyl)imidazo[1,2-b]pyridazin-8-amine 
• 1365243-95-3 4-{6-bromo-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropyl-2-methylbenzamide 
• 955041-74-4 bromo(3-fluoro-4-methoxybenzyl)magnesium 

Relevant articles and documents

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds of general formula I in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations